small for gestational age / intra uterine growth failure
Conditions
Interventions
structural (only at baseline) and functional MRI*s, MEG and extensive
neuropsychologic testing as described below will be performed at baseline,
after one year and three years in both groups A and B
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: Indications for GH treatment is based on the protocol as described by the dutch Working group on Growth Hormone inclusioncriteria for group A (SGA-short; without GH treatment): - Birth weight or birth length below *2 SD adjusted for duration of pregnancy. - Present height below *2.5 SD and below minus 1 SD target height-SDS. - Calendar age between 4 and 6 years. - No evidence of catch up growth during the preceding year. - Children are under regular control by pediatrician, but do not choose to be treated with GH ;Inclusion criteria group B: (SGA-short; with GH treatment) This is a patient population who meet the criteria for SGA-short, (see inclusion criteria group a) and are willing to be treated with GH. ;Inclusion criteria group C (SGA-normal height): - Birth weight or birth length below *2 SD adjusted for duration of pregnancy. - Present height above -2.0 SD and above minus 1 SD of target height -SDS. - Calendar age between 4 and 6 years.;Inclusion criteria group D ( AGA-normal height): - Normal birth weight/length adjusted for duration of pregnancy - Present height above *2 SD for age and within target range (TH plus and minus 2 SD) - Calendar age between 4 and 6 years.;inclusion criteria for group E (SGA-short; with GH treatment): - Birth weight or birth length below *2 SD adjusted for duration of pregnancy. - Present height below *2.5 SD and less than 1 SD below target height-SDS. - Calendar age above 6 years. - No evidence of catch up growth during the preceding year. - Children are under regular control by pediatrician, are willing to be treated with GH
Exclusion criteria
Exclusion criteria: Dysmorphic criteria or a known syndrome (except for Silver Russell syndrome) Skeletal dysplasia Serious complications in the neonatal period Other diseases, responsible for growth failure Medication influencing growth Psychomotor retardation Prematurity
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| relationship between results of neuropsychologic tests and results of neuroimaging techniques | — |
Primary
| Measure | Time frame |
|---|---|
| growth and brain functioning (results of neuropsychologic tests and neuroimaging) | — |
Countries
Netherlands
Outcome results
None listed